Cetera Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $3.64M | Buy |
38,090
+24,242
| +175% | +$2.04M | 0.03% | 574 |
|
|
2023
Q4 | $1.06M | Sell |
13,848
-1,307
| -9% | -$90.9K | 0.01% | 751 |
|
|
2023
Q3 | $1.05M | Sell |
15,155
-371
| -2% | -$29.8K | 0.02% | 706 |
|
|
2023
Q2 | $1.46M | Buy |
15,526
+156
| +1% | +$13.6K | 0.02% | 575 |
|
|
2023
Q1 | $1.27M | Sell |
15,370
-857
| -5% | -$67.4K | 0.02% | 604 |
|
|
2022
Q4 | $1.21M | Sell |
16,227
-4,571
| -22% | -$352K | 0.02% | 593 |
|
|
2022
Q3 | $2K | Buy |
20,798
+9,350
| +82% | +$900K | ﹤0.01% | 1299 |
|
|
2022
Q2 | $1.09M | Buy |
11,448
+1,084
| +10% | +$112K | 0.02% | 546 |
|
|
2022
Q1 | $1.22M | Buy |
10,364
+1,301
| +14% | +$146K | 0.02% | 553 |
|
|
2021
Q4 | $1.17M | Sell |
9,063
-1,545
| -15% | -$180K | 0.02% | 540 |
|
|
2021
Q3 | $1.2M | Buy |
10,608
+1,953
| +23% | +$223K | 0.02% | 547 |
|
|
2021
Q2 | $896K | Buy |
8,655
+1,606
| +23% | +$151K | 0.02% | 583 |
|
|
2021
Q1 | $590K | Sell |
7,049
-7,033
| -50% | -$595K | 0.02% | 675 |
|
|
2020
Q4 | $1.28M | Buy |
14,082
+735
| +6% | +$61K | 0.04% | 364 |
|
|
2020
Q3 | $1.06M | Buy |
13,347
+1,439
| +12% | +$112K | 0.04% | 366 |
|
|
2020
Q2 | $823K | Buy |
+11,908
| New | +$846K | 0.04% | 406 |
|
|
2020
Q1 | – | Sell |
-7,077
| Closed | -$548K | – | 853 |
|
|
2019
Q4 | $548K | Buy |
7,077
+192
| +3% | +$15K | 0.02% | 529 |
|
|
2019
Q3 | $505K | Sell |
6,885
-306
| -4% | -$21.5K | 0.02% | 543 |
|
|
2019
Q2 | $443K | Sell |
7,191
-93
| -1% | -$5.62K | 0.02% | 596 |
|
|
2019
Q1 | $466K | Buy |
7,284
+2,340
| +47% | +$134K | 0.02% | 513 |
|
|
2018
Q4 | $251K | Sell |
4,944
-639
| -11% | -$32.3K | 0.01% | 686 |
|
|
2018
Q3 | $322K | Buy |
5,583
+570
| +11% | +$27.9K | 0.02% | 701 |
|
|
2018
Q2 | $243K | Sell |
5,013
-120
| -2% | -$5.6K | 0.01% | 742 |
|
|
2018
Q1 | $239K | Buy |
+5,133
| New | +$223K | 0.01% | 680 |
|
|
2015
Q2 | – | Sell |
-19,614
| Closed | -$466K | – | 721 |
|
|
2015
Q1 | $466K | Buy |
19,614
+3,264
| +20% | +$73.2K | 0.04% | 399 |
|
|
2014
Q4 | $341K | Buy |
16,350
+318
| +2% | +$6.39K | 0.03% | 448 |
|
|
2014
Q3 | $274K | Buy |
16,032
+1,236
| +8% | +$19.5K | 0.02% | 472 |
|
|
2014
Q2 | $210K | Buy |
+14,796
| New | +$201K | 0.02% | 535 |
|
Other funds holding EW
Cetera Advisors's EW Position: Q1 2024 in Review
Cetera Advisors increased its Edwards Lifesciences (EW) stake by 175% in Q1 2024, buying an estimated $2.04M and bringing the position to 38,090 shares worth $3.64M. The position accounts for 0.03% of the portfolio, ranked #574.
Cetera Advisors first reported a position in EW in Q2 2014 and has held it in 28 quarters since. 1,279 funds tracked by Wall St. Rank hold EW as of Q1 2024.
- Cetera Advisors held 38,090 shares of Edwards Lifesciences worth $3.64M as of Q1 2024.
- Cetera Advisors bought 24,242 Edwards Lifesciences shares in Q1 2024, an estimated $2.04M.
- Edwards Lifesciences made up 0.03% of Cetera Advisors's portfolio in Q1 2024, its #574 holding.
- Cetera Advisors first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 28 quarters since.
- 1,279 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2024.
Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.